VC · AI + Biology + HealthcareVenture Capital · AI + Biology + Healthcare
Jeffrey Low, MD
Investing at the intersection of AI, biology, and healthcare
Partner, Averin
Scout Partner, Sequoia Capital
Perspective
Featured Insights
View all →Latest
LinkedIn·
The China Question: What LPs Are Asking Every Biotech Fund
China-origin assets now account for more than 25% of global pharma licensing deals, and LPs are starting to ask every biotech venture fund what they plan to do about it.
4.1K views · 94 engagements
Andreessen Horowitz·
16 Pitfalls to Avoid When Building a Computational Therapeutics Company
LinkedIn·
Biotech Is Crowding Into Consensus at the Wrong Moment
35.5K views · 713 engagements
Portfolio
Select Investments
View all →
Exscientia
AI-driven drug discovery platform combining precision design with automated experimentation.
IPO (NASDAQ: EXAI), merged with Recursion
“Jeffrey is the rare investor who understands both AI and drug discovery. He backed Exscientia early, helped shape our strategy, brought credibility to subsequent financings, and was a valuable partner through our IPO.”
Board Observer·Novo Holdings
Details▾
Erasca
Precision oncology company developing therapies targeting the RAS/MAPK pathway.
IPO (NASDAQ: ERAS)
“Jeffrey and my relationship spans many years, even before Erasca's launch. In the early days of the company's build, Jeffrey was ahead of the curve and was among the early investors to commit. This exemplifies Jeffrey's instinct for finding and backing exceptional teams rather than just following others.”
Investor·Andreessen Horowitz
Details▾
Freenome
Multiomics platform for early cancer detection through routine blood draws.
$1.3B+ raised post-investment
“I've known Jeffrey since Freenome was a five-person company. He helped lead our Series A, and over the years became one of the closest partners to me and the leadership team. When it mattered most, Jeffrey consistently stepped up well beyond what you'd expect from a typical investor.”
Board Observer·Andreessen Horowitz
Details▾Presence
Recent Appearances
View all →
Jefferies London Healthcare Conference 2025
Meeting the Moment in Biopharma Transactions: A Conversation With Leading Executives and Investors Steering Companies Through Uncertainty
Panelist at the Jefferies London Healthcare Conference 2025, joining leading executives and investors in a conversation on navigating biopharma transactions through uncertainty — covering deal strategy, market timing, and the evolving dynamics shaping healthcare M&A and investment.
Speaking·
Key takeaways
BIO 2025
The Future of RNA Therapeutics
Invited speaker at BIO 2025, presenting on the future of RNA therapeutics for Samyang — covering the scientific and investment landscape for next-generation RNA medicines.
Speaking·
IDC Network Annual Meeting 2025
The State of AI in Life Sciences and Healthcare
Invited speaker at the IDC Network Annual Meeting, an exclusive gathering of the IDC multi-fund platform's investors and portfolio leaders spanning private equity, venture capital, real estate, energy, and impact investing.
Speaking·